Ellen M Ginzler

Ellen M Ginzler

UNVERIFIED PROFILE

Are you Ellen M Ginzler?   Register this Author

Register author
Ellen M Ginzler

Ellen M Ginzler

Publications by authors named "Ellen M Ginzler"

Are you Ellen M Ginzler?   Register this Author

58Publications

1578Reads

-Profile Views

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

Department of Medicine, Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Community Health & Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada; Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea;Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico; Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA; Division of Rheumatology, CHU de Québec et Université Laval, Quebec City, Canada; Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, ON, Canada; Arthritis Research UK Epidemiology Unit, Faculty of Biology Medicine and Health, Manchester Academic Health Sciences Center, The University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Center Manchester, UK; Center for Rheumatology, Department of Medicine, University College London, UK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, UK, London, UK; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA; Northwestern University and Feinberg School of Medicine, Chicago, IL, USA; Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA, USA; Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland UK; Feinstein Institute for Medical Research, Manhasset, NY, USA; Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain; Emory University School of Medicine, Division of Rheumatology, Atlanta, Georgia, USA Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey; Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden; Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden. Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain; Medical University of South Carolina, Charleston, South Carolina, USA; UCSD School of Medicine, La Jolla, CA, USA; Copenhagen Lupus and Vasculitis Clinic, 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; University of Manitoba, Winnipeg, Manitoba, Canada; Hospital for Joint Diseases, NYU, Seligman Center for Advanced Therapeutics, New York NY; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada. Funding for this work was provided by the Nova Scotia Health Authority Research Fund. Dr. Sang-Cheol Bae's work was supported in part by NRF-2017M3A9B4050335, Republic of Korea. Dr. Caroline Gordon's work was supported by Lupus UK and the NIHR /Wellcome Trust Clinical Research Facility. The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Université Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is supported by Arthritis Research UK, the NIHR Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Dr Isenberg and Dr Rahman are supported by and supported by the National Institute for Health, Research University College London Hospitals Biomedical Research Center. The Hopkins Lupus Cohort is supported by the NIH (grant AR43727 and 69572). Dr. Mary Anne Dooley's work was supported by the NIH (grant RR00046). Dr. Ramsey-Goldman's work was supported by the NIH (grants 5UL1TR001422-02, formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464 formerly P60-AR- 48098). Dr. Ruiz-Irastorza is supported by the Department of Education, Universities and Research of the Basque Government. Dr. Soren Jacobsen is supported by the Danish Rheumatism Association (A3865) and the Novo Nordisk Foundation (A05990). Dr. John G. Hanly is supported by the Canadian Institutes of Health Research (grant MOP-88526). Address Correspondence to: Dr. John G Hanly, Division of Rheumatology, Nova Scotia Rehabilitation Centre (2nd Floor), 1341 Summer Street, Halifax, Nova Scotia, Canada, B3H 4K4.Email:

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.181338
Publisher Site
http://dx.doi.org/10.3899/jrheum.181338DOI Listing
April 2019

Dialogue: commentary on 'Engaging African-ancestry participants in systemic lupus erythematosus clinic trials'.

Authors:
Ellen M Ginzler

Lupus Sci Med 2018 17;5(1):e000306. Epub 2018 Dec 17.

Rheumatology Division, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2018-000306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307624PMC
December 2018

Systemic lupus erythematosus.

Rheum Dis Clin North Am 2014 Aug 3;40(3):xiii-xiv. Epub 2014 Jun 3.

Division of Rheumatology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2014.05.004DOI Listing
August 2014

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

J Rheumatol 2014 Feb 1;41(2):300-9. Epub 2013 Nov 1.

From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/cgi/doi/10.3899/jrheum.121368
Publisher Site
http://dx.doi.org/10.3899/jrheum.121368DOI Listing
February 2014

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Clin J Am Soc Nephrol 2013 Jan 9;8(1):147-53. Epub 2012 Aug 9.

Department of Medicine, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.03290412DOI Listing
January 2013

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

Arthritis Res Ther 2012 Feb 7;14(1):R33. Epub 2012 Feb 7.

SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/ar3738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392829PMC
February 2012

Systemic lupus erythematosus. Preface.

Authors:
Ellen M Ginzler

Rheum Dis Clin North Am 2010 Feb;36(1):xiii

Division of Rheumatology, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0889857X0900134
Publisher Site
http://dx.doi.org/10.1016/j.rdc.2009.12.013DOI Listing
February 2010

Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus.

Rheum Dis Clin North Am 2010 Feb;36(1):145-60, ix-x

NYU Langone School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2009.12.011DOI Listing
February 2010

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.

Kidney Int 2010 Jan 4;77(2):152-60. Epub 2009 Nov 4.

Department of Medicine, Columbia University Medical Center, 622 W. 168th St., New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2009.412DOI Listing
January 2010

[Treatment of lupus nephritis].

Reumatol Clin 2008 Jul 28;4(4):140-51. Epub 2008 Oct 28.

Servicio de Reumatología. Complexo Hospitalario de Pontevedra. Pontevedra. España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1699-258X(08)71823-0DOI Listing
July 2008

Pulmonary manifestations of systemic lupus erythematosus.

Semin Respir Crit Care Med 2007 Aug;28(4):441-50

Division of Rheumatology, State University of New York-Downstate Medical Center, Brooklyn, New York 11203, USA.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-2007-985665
Publisher Site
http://dx.doi.org/10.1055/s-2007-985665DOI Listing
August 2007

Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.

Rheum Dis Clin North Am 2006 Feb;32(1):91-102, ix

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2005.11.003DOI Listing
February 2006

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

N Engl J Med 2005 Nov;353(21):2219-28

Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa043731DOI Listing
November 2005

Use of mycophenolate mofetil in autoimmune and renal diseases.

Transplantation 2005 Oct;80(2 Suppl):S265-71

Department of Nephrology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
October 2005

Newer therapeutic approaches for systemic lupus erythematosus.

Rheum Dis Clin North Am 2005 May;31(2):315-28

State University of New York-Downstate Medical Center, Brooklyn, NY 11203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2005.01.003DOI Listing
May 2005

Systemic lupus erythematosus (SLE): Trials and issues.

Discov Med 2004 Dec;4(24):439-43

Department of Rheumatology, Loma Linda University Medical Center, 11234 Anderson Avenue, Loma Linda, CA 11354, USA.

View Article

Download full-text PDF

Source
December 2004

Systemic lupus erythematosus trials: successes and issues.

Curr Opin Rheumatol 2004 Sep;16(5):499-504

SUNY Downstate Medical Center, Rheumatology Division, Brooklyn, New York 11203, USA.

View Article

Download full-text PDF

Source
September 2004

Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus.

Arthritis Rheum 2002 Nov;46(11):2928-36

Department of Medicine, Rehabilitation Center, Room 32-59, 1000 Veteran Avenue, UCLA School of Medicine, Los Angeles, CA 90095-1670, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.10590DOI Listing
November 2002

Familiality and co-occurrence of clinical features of systemic lupus erythematosus.

Arthritis Rheum 2002 Oct;46(10):2678-85

Division of Rheumatology, Department of Medicine, Rehabilitation Center, Room 32-59, University of California-Los Angeles School of Medicine, 1000 Veteran Avenue, Los Angeles, CA 90095-1670, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.10519DOI Listing
October 2002

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.

Arthritis Rheum 2002 Jul;46(7):1820-9

Department of Medicine, John Hopkins Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.10364DOI Listing
July 2002